GlassScriptPhysician profile
Wendell Wells
NPI 1902848922
$1,573.43
in general payments reported to CMS, 2019-2025
28 companies · $22.62 in 2025
The $22.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $520 · 2021: $529 · 2022: $69.15 · 2023: $104 · 2024: $44.81 · 2025: $22.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $270.13 | 2019-2021 | |
| Novo Nordisk INC | $209.11 | 2019-2021 | |
| Lilly USA, LLC | $193.34 | 2020-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $143.24 | 2019-2020 | |
| Exact Sciences Corporation | $101.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.00 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $58.30 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $56.02 | 2021 | |
| Allergan, INC. | $33.31 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $31.84 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $31.17 | 2020 | |
| Sumitomo Pharma America, INC. | $29.15 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $28.22 | 2020 | |
| Merck Sharp & Dohme LLC | $25.98 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $25.00 | 2019-2020 | |
| Eisai INC. | $24.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.36 | 2021 | |
| Corium, LLC | $22.23 | 2022-2023 | Azstarys |
| Amgen INC. | $16.14 | 2019 | |
| Sanofi Pasteur INC. | $14.21 | 2022 | |
| Mylan Specialty L.P. | $14.11 | 2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $12.73 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.11 | 2022 | |
| Boston Scientific Corporation | $11.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.46 | 2021 | |
| Medtronic USA, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.